Updates

Announcements

Launch of New Website & Corporate Update

Oct 23, 2025

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is delighted to announce the launch of its new corporate website, marking another step in the Company’s scientific and corporate evolution and placing its proprietary P140 autoimmune platform at the forefront of its strategy. Website Showcase | P140 Platform – Scientific Advancement and Mechanism of…
Appointment of Independent Non-Executive Director

Oct 13, 2025

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is delighted to announce the appointment of Ketan Patel to the Board, as an independent Non-Executive Director. The appointment is with immediate effect. Ketan is an experienced investment professional and brings extensive expertise in financial markets with a focus in the UK healthcare and life science sectors. He has been a long-term…
TR1 from Lanstead – Major interest in shares

Oct 7, 2025

TR-1: Standard form for notification of major holdings from Lanstead To download form Click here
Exercise of Warrants; Total Voting Rights

Sep 17, 2025

ImmuPharma plc (LSE : IMM), the specialist drug discovery and development company, announces that the Company has received notice of exercise of 500,000 warrants over New Ordinary Shares of 1p each (“Ordinary Shares”) at an exercise price of 5p per share, for a consideration of £25,000. New Ordinary Shares and Admission The New Ordinary Shares have been…
Exercise of Warrants; Total Voting Rights

Sep 11, 2025

ImmuPharma plc (LSE : IMM), the specialty biopharmaceutical company that discovers and develops peptide-based therapeutics, announces that the Company has received notice of exercise of 2,500,000 warrants over New Ordinary Shares of 1p each (“Ordinary Shares”) at an exercise price of 5p per share, for a consideration of £125,000. The New Ordinary Shares have been allotted today and…
Appointments of Chief Scientific Officer and Head of R&D

Sep 1, 2025

ImmuPharma PLC (LSE: IMM), a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics, announces key appointments, in conjunction with the filing of a groundbreaking new patent application for its lead asset P140, separately announced today. Recognising the significance of this major step forward, Dr Sébastien Goudreau has been promoted into the position of Chief…
ImmuPharma Files Groundbreaking New Patent Application for P140: First-in-Class ‘Immunormalizer’ for Precision Diagnosis and Treatment of Autoimmune Diseases

Sep 1, 2025

ImmuPharma PLC (LSE: IMM), a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics, today announces the filing of a groundbreaking new patent application for its lead asset P140, the world’s first “Immunormalizer.” The patent application which provides the potential for 20 years of commercial exclusivity, discloses a novel diagnostic test and precision treatment approach,…
TR1 from Lanstead Capital – Major interest in shares

Aug 20, 2025

Standard form for notification of major holdings To view click here
INTERIM RESULTS for the six months ended 30 June 2025

Aug 6, 2025

ImmuPharma PLC (LSE:IMM), (“ImmuPharma”, the Group or the “Company”), the specialist drug discovery and development company, is pleased to announce its unaudited interim results for the six months ended 30 June 2025 (the “Period”). Key Highlights (including post Period review) Financials For the period ended 30 June 2025, the Group reported a loss of £1.8…
2025 Result of Annual General Meeting

Jun 12, 2025

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, held its AGM earlier today. The Company is pleased to announce that five of the six resolutions (Resolutions 1 – 5 inclusive) were duly passed by shareholders, while the special resolution (which required approval of 75% of votes cast to pass), was not approved. Details…
TR1 from Lanstead – Major interest in shares

May 28, 2025

TR-1: Standard form for notification of major holdings from Lanstead To download form Click here
Notice of AGM and Annual Report & Accounts

May 20, 2025

ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, confirms that the Notice of Annual General Meeting (“AGM”) has today been posted to shareholders. The Annual Report and Accounts for the year ended 31 December 2024 has also been posted to shareholders today. These documents will be available shortly, in electronic form,…
FINAL RESULTS for the twelve months ended 31 December 2024

May 19, 2025

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its Final Results for the twelve months ended 31 December 2024 (the “Period”). Key Highlights (including post Period review) Financials Loss for the Period of £2.5m (2023: £2.9m) Research and development expenses of £1.2m (2023: £2.0m) Administrative…
Extension of Warrants in Incanthera to 30 September 2025

Apr 1, 2025

ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company, is pleased to announce that the Company has agreed – by means of a Deed of Variation – with Incanthera plc (“Incanthera”), that warrants issued to the Company on 26 February 2020 (“Warrants”), in conjunction with Incanthera’s IPO onto the Aquis Exchange (“AQSE”), are…
ImmuPharma Attending Bio-Europe Spring – 17-19 March 2025, Milan

Mar 14, 2025

Further opportunities to present recent insights into the MOA* of the P140 technology platform ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that Tim McCarthy, CEO, Dr Tim Franklin, COO, and Dr Sebastien Goudreau, CEO of the R&D subsidiary ImmuPharma Biotech will be attending the Bio-Europe Spring Conference from 17-19 March 2025,…
ImmuPharma proves unique Mechanism of Action of P140

Mar 13, 2025

ImmuPharma PLC (LSE:IMM), a leading specialist in peptide based drug discovery and development, announces a significant milestone in evidencing the unique mechanism of action (“MOA”) of its P140 autoimmune technology platform. Importantly, these new discoveries announced today, in respect to the MOA of P140, highlight that: P140 has a unique MOA: The results provide direct…
TR1 from Lanstead – Major interest in shares

Feb 22, 2025

TR-1: Standard form for notification of major holdings from Lanstead To download form click here
Lanstead Subscription & Oversubscribed Placing to ‘c.£2.91 million | Sharing Agreement | Related Party Transactions

Feb 13, 2025

ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is pleased to announce an equity fundraise of c.£2.91 million, utilising existing authorities to allot shares (the “Fundraise”). The Fundraise comprises a) an oversubscribed placing to raise gross proceeds of £1.034 million through the issue of 27,586,667 new ordinary shares of 1 pence…
Response to Share Price Movement

Jan 28, 2025

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, notes the recent movements in its share price. As announced on 9 January 2025, the Company has made innovative groundbreaking advancements in its preclinical research program focused on P140 and the pathogenesis of autoimmune diseases. This new discovery, conducted by the Company’s R&D subsidiary ImmuPharma…
ImmuPharma Announces Breakthrough Findings into Autoimmune Diseases

Jan 9, 2025

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces innovative groundbreaking advancements in its preclinical research program focused on P140 and the pathogenesis of autoimmune diseases. This new discovery, conducted by the Company’s R&D subsidiary ImmuPharma Biotech, has yielded compelling data that provides novel insights into autoimmune disease mechanisms. Importantly for our autoimmune…
Immupharma at JP MORGAN CONFERENCE and BIOTECH SHOWCASE 11-16 January 2025, San Francisco

Jan 8, 2025

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that Tim McCarthy, CEO, Dr Tim Franklin, COO, and Dr Sebastien Goudreau, CEO of the R&D subsidiary ImmuPharma Biotech will be attending both the JP Morgan Conference and the Biotech Showcase from 11-16 January 2025, in San Francisco. The JP Morgan conference and Biotech…

2025 (21)

2024 (19)

2023 (25)

2022 (27)

2021 (21)

2020 (40)

2019 (19)

2018 (22)

2017 (17)

2016 (25)

2015 (17)

2014 (12)

2011 (2)

Lisa Baderoon

Non-Executive Director and Head of Investor Relations

Lisa has spent over 25 years working within the City of London being involved with a diverse portfolio of clients from a variety of sectors but with a leaning towards emerging, high growth businesses advising both private and public companies on their financial and corporate strategies aligned to stakeholder and investor interests, as well as a strong acumen in media communication. During this time, she has been involved in a multitude of client transactions spanning private fund raisings, Initial Public Offerings (IPOs), secondary high profile capital raisings and mergers and acquisitions both in the UK and internationally.

Lisa had a successful career spanning 20 years as a Partner at Buchanan Communications, one of the leading City financial public relations agencies. As one of the youngest Board members, she was involved in the successful five-year earnout, as part of Buchanan being acquired by the FTSE 100 rated WPP Plc in 1997.

Lisa founded Just B Communications Ltd in 2012 with the key objective of working with a more select number of clients and providing a greater degree of bespoke advisory services thus becoming more integral to the day to day corporate and strategic development for these businesses. She has successfully advised a number of public and private companies, at Board level, on corporate strategy, stakeholder and investor communications, capital raisings, dual listings, licensing and M&A. Media profiling, where required, has also played an important role in advisory activities.

Lisa was appointed Head of Investor Relations at ImmuPharma in 2012 and most recently appointed as a Non-Executive Director in July 2021.

Ketan Patel

Independent Non-Executive Director

Ketan is an experienced investment professional who brings extensive expertise in financial markets, with a particular focus on the UK healthcare and life science sectors. He has been a long-term investor in UK markets, working as both an analyst and Fund Manager, managing institutional, retail, and charity mandates. Ketan began his career at JP Morgan before moving to Insight Investment, where he served as a global Pharmaceutical and Healthcare analyst. He then spent over 20 years at EdenTree Investment Management, where he was responsible for UK equity and global equity income strategies, consistently delivering upper-quartile performance.

Ketan combines rigorous fundamental analysis with risk-focused investment strategies. He is also a published thought leader on sustainability and investment themes. Ketan is a CFA Charterholder and holds an MSc in Economic History from the London School of Economics, an MSc in Geography from King’s College London, and a BA (Hons) in History and Geography from Queen Mary University, London.

Dr Laurence Reilly MBA

Senior Independent Non-Executive Director

Dr Laurence Reilly has been appointed as Senior independent Non-Executive Director and Chair of the Audit Committee. Dr Reilly brings extensive experience in managing late-stage clinical programs through to approval, in addition to commercial and business development experience.

He is currently Vice President of Research & Investments, working with Royalty Pharma, a New York based life science investment company focussing on acquisition of biopharmaceutical royalties and funding of innovation across the biopharmaceutical industry.

Through his consulting practice (Acumen Life Science Investment Consulting) Dr Reilly has provided strategic consulting and due-diligence services to biotech companies, life science venture capital and private equity clients. He also served as Chief Medical Officer for Cellectar Biosciences, New Jersey, a late-stage oncology biotech company. Prior to founding his consulting practice, Dr Reilly served as Chief Scientific Officer and Vice President at Avillion, a drug development company focused on the co-development and financing of drug candidates, where he was responsible for clinical and strategic oversight of co-development programs and partnering with both large pharma and biotech, including Pfizer, Merck KGaA and AstraZeneca. Dr. Reilly previously served as a Clinician – Clinical Development & Medical Oversight at Pfizer and at Lundbeck as Medical & Scientific Advisor.

Dr Reilly earned his medical degree from the University of Liverpool Medical School, U.K., and practiced as Neurosurgery Resident at Queen Elizabeth University Hospital in Birmingham. Dr Reilly also holds a Masters Degree in Law from De Montfort University, U.K.

Dr Tim Franklin PhD, MBA

Chief Operating Officer

Tim has 30 years’ experience in the biopharmaceutical industry. He worked in clinical research, sales & marketing, and global strategic marketing for Warner Lambert, Wellcome and SmithKline Beecham. He later moved to the capital markets where he became a top-ranked pharmaceuticals analyst at Dresdner Kleinwort investment bank. He applied his experience to stock selection at hedge funds and advised several small biotechnology companies on corporate and commercial strategy and access to capital. He holds a BSc in Medicinal Chemistry and a PhD in Pharmacology from Loughborough University and an MBA from Warwick Business School.

Dr Laura Mauran-Ambrosino Ph.D.

Head of R&D

Born in Montpellier, France, Dr Mauran- Ambrosino obtained her PhD in Chemistry at the Université de Bordeaux as a CIFRE fellow in co-supervision by Dr Goudreau.

She then conducted postdoctoral studies at the “Centre Hospitalier Universitaire” Pellegrin in cell biology. In 2018, she joined Ureka and established the biology department and the analytical chemistry department and in 2021, she became Chief Scientific Officer of Ureka Pharma. Dr Mauran-Ambrosino was a key contributor to the development of BioGlucagon, and BioAMB.

Ashley Clarke ACA

Chief Financial Officer & Company Secretary

Ashley brings over a decade of experience in the financial sector. She began her career at a Big Four accounting firm and later advanced her professional expertise by earning her ACA qualification with a respected local firm.

Her professional journey is rooted in auditing, where she developed expertise working with a diverse portfolio of audit and non-audit clients across various industries. Ashley’s experience spans from supporting SMEs to managing large international group consolidations, giving her a comprehensive understanding of financial management across different business scales.

Ashley has been closely involved with the company’s accounts for several years via outsourced accountants, providing her with deep familiarity with its operations. Now, as Group CFO and Company Secretary, she is poised to leverage her extensive knowledge to drive strategic financial growth and ensure robust fiscal management.

Dr Sébastien R. Goudreau Ph.D.

Chief Scientific Officer

Born in Sherbrooke, Québec, Canada, Dr Goudreau obtained his PhD in Chemistry at the Université of Montréal as a NSERC fellow before moving to Switzerland to conduct postdoctoral studies at the ETH Zürich as an FRQNT fellow. He then moved back to Canada for one year where he co-founded FindMolecule inc. and worked for the pharma industry.

In 2014 he joined ImmuPharma as research director and established the research laboratories of Ureka in Bordeaux. After the merger of ELRO with Ureka in 2019, Dr Goudreau became Chief Scientific Officer of Ureka Pharma and in 2021, he became Chief Executive Officer of ImmuPharma Biotech. Notably, Dr Goudreau and his team are credited for the discovery and development of, among others, URK 614, BioGlucagon, and BioAMB.

Tim McCarthy FCCA, MBA

Chief Executive Officer

Tim has 40 years’ international senior level business experience in high growth biotech, healthcare and technology companies. He is also Chairman of Incanthera plc. Tim was formerly Chairman of 4basebio plc and CEO and CFO of a number of UK public listed and private companies including, Alizyme plc and Peptide Therapeutics Group plc, and has a core understanding of AIM and its regulatory processes. Co-founding a number of healthcare and biotechnology companies, he has helped raise substantial amounts of equity capital and also advised and worked at Board level for a diverse range of companies internationally, in areas such as business strategy, mergers & acquisitions, due diligence and licensing.

Announcements

Launch of New Website & Corporate Update

Appointment of Independent Non-Executive Director

TR1 from Lanstead – Major interest in shares

Exercise of Warrants; Total Voting Rights

Exercise of Warrants; Total Voting Rights

Appointments of Chief Scientific Officer and Head of R&D

ImmuPharma Files Groundbreaking New Patent Application for P140: First-in-Class ‘Immunormalizer’ for Precision Diagnosis and Treatment of Autoimmune Diseases

TR1 from Lanstead Capital – Major interest in shares

INTERIM RESULTS for the six months ended 30 June 2025

2025 Result of Annual General Meeting

TR1 from Lanstead – Major interest in shares

Notice of AGM and Annual Report & Accounts

FINAL RESULTS for the twelve months ended 31 December 2024

Extension of Warrants in Incanthera to 30 September 2025

ImmuPharma Attending Bio-Europe Spring – 17-19 March 2025, Milan

ImmuPharma proves unique Mechanism of Action of P140

TR1 from Lanstead – Major interest in shares

Lanstead Subscription & Oversubscribed Placing to ‘c.£2.91 million | Sharing Agreement | Related Party Transactions

Response to Share Price Movement

ImmuPharma Announces Breakthrough Findings into Autoimmune Diseases

Immupharma at JP MORGAN CONFERENCE and BIOTECH SHOWCASE 11-16 January 2025, San Francisco

2025 (21)

2024 (19)

2023 (25)

2022 (27)

2021 (21)

2020 (40)

2019 (19)

2018 (22)

2017 (17)

2016 (25)

2015 (17)

2014 (12)

2013 (7)

2012 (8)

2011 (2)